Literature DB >> 10173092

Hospital care for persons with AIDS in the European Union.

M J Postma1, K Tolley, R M Leidl, A M Downs, E J Beck, A M Tramarin, Y A Flori, M Santin, F Antoñanzas, H Kornarou, V C Paparizos, M G Dijkgraaf, J Borleffs, A J Luijben, J C Jager.   

Abstract

This study estimates the current and future hospital resources for AIDS patients in the European Union (EU), using multinational scenario analysis (EU Concerted Action BMH1-CT-941723). In collaboration with another EU-project ('Managing the Costs of HIV Infection'), six national European studies on the utilization of hospital care for AIDS have been selected to provide the data for our analysis. The selection criteria involve recentness, quality, comparability, accessibility and representativeness. Baseline hospital resource utilization is estimated for hospital inpatient days and outpatient contracts, using a standardized approach controlling for two severity stages of AIDS (chronic stage and late stage). The epidemiological part of the study is based on standard models for backcalculating HIV incidence and projecting AIDS incidence, prevalence and mortality. In the next step, baseline resource utilization is linked to epidemiological information in a mixed prevalence and mortality-based approach. Several scenarios render different future epidemiological developments and hospital resource needs. For the year 1999, hospital bed needs of 10,000-12,700 in the EU are indicated, representing an increase of 20-60% compared to the estimated current (1995) level. The projected range for 1999 corresponds to a maximum of 0.65% of all hospital beds available in the EU. The growth in the number of outpatient hospital contacts is projected to possibly exceed that of inpatient days up to 1.82 million in 1999. Our methodology illustrates that estimation of current and future hospital care for AIDS has to be controlled for severity stages, to prevent biases. Further application of the multinational approach is demonstrated through a 'what-if' analysis of the potential impact of combination triple therapy for HIV/AIDS. Estimation of the economic impact of other diseases could as well benefit from the severity-stages approach.

Entities:  

Mesh:

Year:  1997        PMID: 10173092     DOI: 10.1016/s0168-8510(97)00019-5

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  5 in total

Review 1.  Health economics in HIV disease. A review of the European literature.

Authors:  M Youle; P Trueman; K Simpson
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

2.  Modeling the HIV/AIDS epidemic via survivor functions.

Authors:  G Schinaia
Journal:  Eur J Epidemiol       Date:  2000-06       Impact factor: 8.082

3.  Hospital care for persons with AIDS in European-Union countries; a cross-country comparison.

Authors:  M J Postma; H Kornarou; V Paparizos; R M Leidl; K Tolley; J Kyriopoulos; J C Jager
Journal:  Health Care Manag Sci       Date:  2000-01

4.  The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs.

Authors:  E J Beck; K Tolley; A Power; S Mandalia; P Rutter; J Izumi; J Beecham; A Gray; D Barlow; P Easterbrook; M Fisher; J Innes; G Kinghorn; B Mandel; A Pozniak; A Tang; D Tomlinson; I Williams
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

5.  Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.

Authors:  Eduard J Beck; Sundhiya Mandalia; Roshni Sangha; Mike Youle; Ray Brettle; Mark Gompels; Margaret Johnson; Anton Pozniak; Achim Schwenk; Stephen Taylor; John Walsh; Ed Wilkins; Ian Williams; Brian Gazzard
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.